Literature DB >> 28526488

Targeting the gut-liver axis in liver disease.

Reiner Wiest1, Agustin Albillos2, Michael Trauner3, Jasmohan S Bajaj4, Rajiv Jalan5.   

Abstract

The gut-liver axis is widely implicated in the pathogenesis of liver diseases, where it is increasingly the focus of clinical research. Recent studies trialling an array of therapeutic and preventative strategies have yielded promising results. Considering these strategies, the armamentarium for targeting the gut-liver axis will continue to expand. Further clinical trials, translated from our current knowledge of the gut-liver axis, promise an exciting future in liver treatment.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacterial translocation; Bile acids; Cirrhosis; Faecal microbial transplantation; Fibrosis; Gut-liver-axis; Incretines; Liver injury; Microbiome; Pre-, probiotics

Mesh:

Year:  2017        PMID: 28526488     DOI: 10.1016/j.jhep.2017.05.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  103 in total

Review 1.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 2.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

3.  Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.

Authors:  Jasmohan S Bajaj; Leroy R Thacker; Andrew Fagan; Melanie B White; Edith A Gavis; Phillip B Hylemon; Robert Brown; Chathur Acharya; Douglas M Heuman; Michael Fuchs; Swati Dalmet; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  JCI Insight       Date:  2018-03-08

Review 4.  The knowns and unknowns of treatment for alcoholic hepatitis.

Authors:  Tejasav S Sehrawat; Mengfei Liu; Vijay H Shah
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-05

Review 5.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

6.  Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.

Authors:  Jasmohan S Bajaj; Nita H Salzman; Chathur Acharya; Richard K Sterling; Melanie B White; Edith A Gavis; Andrew Fagan; Michael Hayward; Mary L Holtz; Scott Matherly; Hannah Lee; Majdi Osman; Mohammad S Siddiqui; Michael Fuchs; Puneet Puri; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

7.  Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study.

Authors:  Chikara Iino; Tetsu Endo; Kenichiro Mikami; Takuma Hasegawa; Masayo Kimura; Naoya Sawada; Shigeyuki Nakaji; Shinsaku Fukuda
Journal:  Hepatol Int       Date:  2019-09-12       Impact factor: 6.047

8.  FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Authors:  Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

Review 9.  Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis.

Authors:  Charlotte Woodhouse; Arjuna Singanayagam; Vishal C Patel
Journal:  Clin Med (Lond)       Date:  2020-09       Impact factor: 2.659

10.  Fructose stimulated de novo lipogenesis is promoted by inflammation.

Authors:  Jelena Todoric; Giuseppe Di Caro; Saskia Reibe; Darren C Henstridge; Courtney R Green; Alison Vrbanac; Fatih Ceteci; Claire Conche; Reginald McNulty; Shabnam Shalapour; Koji Taniguchi; Peter J Meikle; Jeramie D Watrous; Rafael Moranchel; Mahan Najhawan; Mohit Jain; Xiao Liu; Tatiana Kisseleva; Maria T Diaz-Meco; Jorge Moscat; Rob Knight; Florian R Greten; Lester F Lau; Christian M Metallo; Mark A Febbraio; Michael Karin
Journal:  Nat Metab       Date:  2020-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.